Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), with a clinical outcome ranging from mild to severe, including death. To date, it is unclear why some patients develop severe symptoms. Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland. In this cohort, significantly lower 25(OH)D levels (p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years. On the basis of this preliminary observation, vitamin D supplementation might be a useful measure to reduce the risk of infection. Randomized controlled trials and large population studies should be conducted to evaluate these recommendations and to confirm our preliminary observation.

25-hydroxyvitamin D concentrations are lower in patients with positive PCR for SARS-CoV-2

D'avolio A.
First
;
Avataneo V.;Manca A.;Cusato J.;De Nicolo A.;
2020-01-01

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19), with a clinical outcome ranging from mild to severe, including death. To date, it is unclear why some patients develop severe symptoms. Many authors have suggested the involvement of vitamin D in reducing the risk of infections; thus, we retrospectively investigated the 25-hydroxyvitamin D (25(OH)D) concentrations in plasma obtained from a cohort of patients from Switzerland. In this cohort, significantly lower 25(OH)D levels (p = 0.004) were found in PCR-positive for SARS-CoV-2 (median value 11.1 ng/mL) patients compared with negative patients (24.6 ng/mL); this was also confirmed by stratifying patients according to age >70 years. On the basis of this preliminary observation, vitamin D supplementation might be a useful measure to reduce the risk of infection. Randomized controlled trials and large population studies should be conducted to evaluate these recommendations and to confirm our preliminary observation.
2020
Inglese
Esperti anonimi
12
5
1359
1365
7
Concentrations; Coronavirus; COVID-19; Deficiency; SARS-CoV-2; Vitamin D; Age Factors; Aged; Aged, 80 and over; Betacoronavirus; Coronavirus Infections; Dietary Supplements; Female; Humans; Male; Middle Aged; Pandemics; Pneumonia, Viral; Polymerase Chain Reaction; Retrospective Studies; Switzerland; Vitamin D
SVIZZERA
1 – prodotto con file in versione Open Access (allegherò il file al passo 6 - Carica)
262
8
D'avolio A.; Avataneo V.; Manca A.; Cusato J.; De Nicolo A.; Lucchini R.; Keller F.; Cantu M.
info:eu-repo/semantics/article
open
03-CONTRIBUTO IN RIVISTA::03A-Articolo su Rivista
File in questo prodotto:
File Dimensione Formato  
nutrients-12-01359-v2.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 1.12 MB
Formato Adobe PDF
1.12 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1738840
Citazioni
  • ???jsp.display-item.citation.pmc??? 222
  • Scopus 329
  • ???jsp.display-item.citation.isi??? 297
social impact